BRIEF-Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026

June 2 (Reuters) - Santhera Pharmaceuticals Holding AG SANN.S:

  • SANTHERA ANNOUNCES ORPHAN DRUG AND PRIORITY REVIEW DESIGNATIONS FOR AGAMREE® (VAMOROLONE) IN SOUTH KOREA

  • SANTHERA PHARMACEUTICALS - GIFT DESIGNATION MAY SHORTEN REVIEW TIMELINE TO 90 WORKING DAYS IN SOUTH KOREA

  • SANTHERA PHARMACEUTICALS : NXERA PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION IN SOUTH KOREA DURING 2026

Source text: ID:nGNX5NQxk

Further company coverage: SANN.S


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.